Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Europe Backs Celgene’s Pomalidomide And Aegerion’s Lomitapide

This article was originally published in The Pink Sheet Daily

Executive Summary

Positive opinions from Europe's top drug assessment panel in May have included a long-acting "biobetter" lipegfilgrastim from Teva, a once-weekly HGH injection from Biopartners GmbH, and a smallpox vaccine developed by Bavarian Nordic with funding from the U.S. BioShield program.

Advertisement

Related Content

Aegerion’s Lojuxta Submission To Germany's IQWIG Disappoints
Smallpox Discovery Prompts FDA Action Plan; Move To White Oak Unchanged
U.S. Biotech Ariad Builds European Presence For Imminent Iclusig Launches
European Notebook: AstraZeneca Snuggles Up To Potential Partners In New Cambridge HQ, Viagra Patents Expire In Europe
Multiple Myeloma Market Snapshot: New Combos Offer Greater Longevity, But Payers May Push Back
Celgene Has A Swift Start For Pomalyst Launch
EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum
Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain
Uncle Sam's Orders: Emergent Scores $107 Mil. For Anthrax Plant, While Bavarian Nordic Delivers On Smallpox
Teva Wins Ratiopharm For $5 Billion And Gains A Key Foothold In Europe

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075770

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel